IgG immune complex-induced acute lung injury is ameliorated by cAMP via down-regulation of C/EBP- and AP-1-mediated transcriptions

Chunguang Yan, Jing Chen, Huifang Tang, Chunmin Deng, Qi Zhang, Ximo WangJournal of Inflammation 2023 · DOI

Abstract

Our data demonstrate, for the first time, that cAMP-PKA signal is involved in down-regulation of IgG-IC-associated inflammatory responses via down-regulating MAPK activation, which is critical for transcriptional activities of C/EBP and AP-1. Collectively, our experiments provide theoretical base for the potential application of PDE4-selective inhibitor to clinic for treatment of IgG-IC-related acute lung injury.

Introduction

Acute Lung Injury (ALI) and its more severe manifestation, Acute Respiratory Distress Syndrome (ARDS), remain significant clinical challenges characterized by intense pulmonary inflammation, alveolar damage, and high mortality rates. A primary driver of this pathology is the deposition of IgG immune complexes (IgG-IC) within the lung parenchyma. This deposition triggers alveolar macrophages to release a cascade of pro-inflammatory mediators, leading to a "cytokine storm" and subsequent tissue destruction.

While cyclic adenosine monophosphate (cAMP) is recognized as a potent anti-inflammatory second messenger, its specific role and downstream signaling mechanisms in the context of IgG-IC-mediated lung injury have remained poorly understood. This study investigates whether elevating cellular cAMP levels can protect the lungs from IgG-IC damage and identifies the specific molecular pathways involved.

Histological representation of lung tissue damage in the IgG-IC-induced acute lung injury model.

Methods

The researchers utilized a multi-faceted approach involving both in vivo and in vitro models:

  • Animal Model: ALI was induced in C57BL/6 mice through the airway deposition of IgG immune complexes.
  • Pharmacological Intervention: To sustain high intracellular cAMP levels, the team employed PDE4-selective inhibitors, specifically Rolipram and Roflumilast. PDE4 is the primary enzyme responsible for cAMP degradation in inflammatory cells.
  • Pathway Dissection: Specific agonists and inhibitors were used to distinguish between the two main cAMP effectors: Protein Kinase A (PKA) and Exchange Protein directly activated by cAMP (Epac).
  • Molecular Analysis: Key metrics included lung permeability (measured via albumin levels), neutrophil accumulation (MPO activity), and cytokine production (ELISA/RT-qPCR). Luciferase reporter assays were conducted in HEK293 cells to quantify the transcriptional activity of C/EBP and AP-1.

Key Results

Amelioration of Lung Injury

The administration of Rolipram significantly mitigated the severity of ALI. Most notably, Rolipram treatment reduced the lung permeability index—a critical indicator of vascular leakage and alveolar damage—by more than 50% in mice challenged with IgG-IC.

Effect of Rolipram on lung permeability index in mice challenged with IgG-IC.

Furthermore, neutrophil recruitment into the alveolar spaces, a hallmark of acute inflammation, was reduced by approximately 60% following Rolipram treatment.

The PKA-MAPK Signaling Axis

Contrary to other inflammatory models (such as LPS-induced injury) where Epac often plays a dominant role, this study identified PKA as the essential mediator of cAMP's protective effects in IgG-IC-induced injury. The cAMP-PKA axis was found to suppress the activation of the Mitogen-Activated Protein Kinase (MAPK) pathway, specifically inhibiting the phosphorylation of p38, ERK1/2, and JNK.

Transcriptional Suppression

By deactivating the MAPK pathway, cAMP effectively prevents the activation of two major transcription factors: C/EBP and AP-1. In macrophage models (RAW264.7 cells), raising cAMP levels slashed the mRNA expression of pro-inflammatory cytokines such as TNF-α, MIP-1α, and MIP-1β by over 90%. Luciferase assays confirmed that Rolipram reduced AP-1 and C/EBP transcriptional activities by 41% and 26%, respectively.

Discussion and Conclusion

This research provides a clear mechanistic link between cAMP elevation and the suppression of IgG-IC-induced pulmonary inflammation. By identifying the PKA-MAPK-C/EBP/AP-1 signaling cascade, the study offers a robust theoretical foundation for using PDE4 inhibitors as a therapeutic strategy for ALI.

While PDE4 inhibitors like Roflumilast are already clinically approved for conditions like COPD, their use in ALI is limited by potential systemic side effects. Future research focusing on specific PDE4 isoforms (A, B, C, or D) may allow for more targeted therapies with improved safety profiles, potentially offering a new standard of care for patients suffering from immune complex-mediated respiratory distress.

Summary updated

Abstract

Our data demonstrate, for the first time, that cAMP-PKA signal is involved in down-regulation of IgG-IC-associated inflammatory responses via down-regulating MAPK activation, which is critical for transcriptional activities of C/EBP and AP-1. Collectively, our experiments provide theoretical base for the potential application of PDE4-selective inhibitor to clinic for treatment of IgG-IC-related acute lung injury.
BibTeX
@article{yan2023igg,
  author = {Chunguang Yan and Jing Chen and Huifang Tang and Chunmin Deng and Qi Zhang and Ximo Wang},
  title = {{IgG immune complex-induced acute lung injury is ameliorated by cAMP via down-regulation of C/EBP- and AP-1-mediated transcriptions}},
  journal = {Journal of Inflammation},
  year = {2023},
  doi = {10.1186/s12950-023-00359-6},
}
Figure